These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 30284145)

  • 1. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
    Lau CH; Suh Y
    Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
    Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
    Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for Allele-Specific Epigenome Editing Using CRISPR/dCas9.
    Rajaram N; Bashtrykov P; Jeltsch A
    Methods Mol Biol; 2024; 2842():179-192. PubMed ID: 39012596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis.
    Kabadi AM; Machlin L; Dalal N; Lee RE; McDowell I; Shah NN; Drowley L; Randell SH; Reddy TE
    J Cyst Fibros; 2022 Jan; 21(1):164-171. PubMed ID: 34049825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing.
    Goubert D; Koncz M; Kiss A; Rots MG
    Methods Mol Biol; 2018; 1767():395-415. PubMed ID: 29524148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fine-Tuning the Epigenetic Landscape: Chemical Modulation of Epigenome Editors.
    Noviello G; Gjaltema RAF
    Methods Mol Biol; 2024; 2842():57-77. PubMed ID: 39012590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of Cell Lines Stably Expressing a dCas9-Fusion or sgRNA to Address Dynamics of Long-Term Effects of Epigenetic Editing.
    Sarno F; Koncz M; Eilers RE; Verschure PJ; Rots MG
    Methods Mol Biol; 2024; 2842():289-307. PubMed ID: 39012602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic mice for in vivo epigenome editing with CRISPR-based systems.
    Gemberling MP; Siklenka K; Rodriguez E; Tonn-Eisinger KR; Barrera A; Liu F; Kantor A; Li L; Cigliola V; Hazlett MF; Williams CA; Bartelt LC; Madigan VJ; Bodle JC; Daniels H; Rouse DC; Hilton IB; Asokan A; Ciofani M; Poss KD; Reddy TE; West AE; Gersbach CA
    Nat Methods; 2021 Aug; 18(8):965-974. PubMed ID: 34341582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/dCas9 platforms in plants: strategies and applications beyond genome editing.
    Moradpour M; Abdulah SNA
    Plant Biotechnol J; 2020 Jan; 18(1):32-44. PubMed ID: 31392820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/dCas9 Switch Systems for Temporal Transcriptional Control.
    Gjaltema RAF; Schulz EG
    Methods Mol Biol; 2018; 1767():167-185. PubMed ID: 29524134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.
    Rahman MM; Tollefsbol TO
    Methods; 2021 Mar; 187():77-91. PubMed ID: 32315755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas mediated epigenome editing for cancer therapy.
    Ansari I; Chaturvedi A; Chitkara D; Singh S
    Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs.
    Pflueger C; Tan D; Swain T; Nguyen T; Pflueger J; Nefzger C; Polo JM; Ford E; Lister R
    Genome Res; 2018 Aug; 28(8):1193-1206. PubMed ID: 29907613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editing the Epigenome to Tackle Brain Disorders.
    Liu XS; Jaenisch R
    Trends Neurosci; 2019 Dec; 42(12):861-870. PubMed ID: 31706628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenome editing for targeted DNA (de)methylation: a new perspective in modulating gene expression.
    Seem K; Kaur S; Kumar S; Mohapatra T
    Crit Rev Biochem Mol Biol; 2024; 59(1-2):69-98. PubMed ID: 38440883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances of epigenetic editing.
    Gjaltema RAF; Rots MG
    Curr Opin Chem Biol; 2020 Aug; 57():75-81. PubMed ID: 32619853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allele-Specific Epigenome Editing.
    Bashtrykov P; Jeltsch A
    Methods Mol Biol; 2018; 1767():137-146. PubMed ID: 29524132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reader-Effectors as Actuators of Epigenome Editing.
    Kim SH; Haynes KA
    Methods Mol Biol; 2024; 2842():103-127. PubMed ID: 39012592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modular dCas9-based recruitment platform for combinatorial epigenome editing.
    Swain T; Pflueger C; Freytag S; Poppe D; Pflueger J; Nguyen TV; Li JK; Lister R
    Nucleic Acids Res; 2024 Jan; 52(1):474-491. PubMed ID: 38000387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.